Skip to content

Change in AP at other companies

Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$8.82M+125%
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
$4.38M+140%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$4.63M+162%
Nuvation Bio logo
Nuvation BioNUVB
$12.96M+209%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
-$287K+96.7%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
-$4.8M+44.1%

Other financials

Income statement

See full
Revenue$6.3M-66.1%
Operating income-$92.5M-47.1%
Net income-$87.2M-54.7%
EPS (diluted)-$0.79-17.9%

Balance sheet

See full
Cash & equivalents$72.2M-6.1%
Total debt$58.7M+120%
Total equity$480.9M0.0%
Total assets$636.1M+3.4%

Cash flow

See full
Operating cash flow-$71.9M-17.7%
CapEx$1.0M-70.0%
Free cash flow-$73.0M-13.0%

Valuation

See full
Market cap$1.95B+40.1%
Enterprise value$1.94B+45.1%
P/S27.2×+2.5×

Profitability

See full
Operating margin-439.3%+35.3pp
Net margin-411.4%+52.7pp
FCF margin-378.7%+24.1pp

Returns & leverage

See full
Return on equity-61.4%-2.5pp
Debt / equity0.1×+0.1×
Current ratio-0.3×

Where this comes from

Reported directly by Nurix Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayable.

The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nurix Therapeutics, Inc.'s change in ap.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nurix Therapeutics, Inc.'s change in AP?
Nurix Therapeutics, Inc. (NRIX) reported change in AP of -$461K in Q4 2025.
How has Nurix Therapeutics, Inc.'s change in AP changed year-over-year?
Nurix Therapeutics, Inc.'s change in AP increased by 85.6% year-over-year, from -$3.21M to -$461K.
What does change in AP mean?
Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.